Abstract
Purpose
To analyze the use of alvimopan, a peripheral mu-opioid receptor antagonist, in expediting gastrointestinal recovery after benign abdominal urinary tract reconstruction. Alvimopan use has been well defined in the management of radical cystectomy and urinary diversion for oncologic indications. It has not been studied in benign abdominal genitourinary reconstruction.
Methods
Patients who underwent urinary reconstruction utilizing harvested bowel segments for benign conditions from 12/2014–7/2019 were retrospectively reviewed. From 5/2018–7/2019 our institution approved the use of perioperative alvimopan in the aforementioned patients (N = 11), who were paired 1:2 with patients from a cohort of alvimopan-eligible patients who did not receive the drug (N = 22). Patients were paired by (1) type of reconstruction and (2) presence of neurogenic bowel-bladder (NBB).
Results
Of the 70 patients who underwent urinary reconstruction during the study period, 46 patients (66%) were eligible to receive alvimopan. Length of stay was shorter for the alvimopan group compared to the non-alvimopan group (median 5 days [IQR 4–5 days] vs. 8 days [IQR 6–11 days]; P = 0.002). Time to first bowel movement was shorter for the alvimopan group (median 4 days [IQR 3–4 days] vs. 6 days [IQR 4–7], P = 0.001). No patient treated with alvimopan required a nasogastric (NG) tube for post-operative ileus compared to 7 (32%) patients in the non-treatment group (P = 0.035). Post-operative complications and 30-day readmissions were similar between the two groups.
Conclusion
The use of perioperative alvimopan in benign abdominal urinary tract reconstruction expedited return of bowel function and decreased length of stay compared to a matched cohort of untreated patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The authors are willing to provide raw data to the editors and readers.
References
Erowele GI (2008) Alvimopan (entereg), a peripherally acting mu-opioid receptor antagonist for postoperative ileus. P T 33(10):574–583
Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS (2012) A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum 55(5):611–620. https://doi.org/10.1097/DCR.0b013e318249fc78
Daneshmand S, Ahmadi H, Schuckman AK et al (2014) Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol 192(1):50–55. https://doi.org/10.1016/j.juro.2014.01.097
Chang S, Bochner B, Chou R, Driecer R, Kamat A, Lerner S. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) - American Urological Association.; 2017. Accessed March 24, 2020. https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive-guideline
Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA (2002) Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 167(5):2012–2016
Roghmann F, Trinh Q-D, Braun K et al (2014) Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol 21(2):143–149. https://doi.org/10.1111/iju.12232
Hirobe M, Tanaka T, Shindo T et al (2018) Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan. Int J Clin Oncol 23(4):734–741. https://doi.org/10.1007/s10147-018-1245-z
Sultan S, Coles B, Dahm P (2017) Alvimopan for recovery of bowel function after radical cystectomy. Cochrane Database Syst Rev 2017:5. https://doi.org/10.1002/14651858.CD012111.pub2
Lee CT, Chang SS, Kamat AM et al (2014) Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 66(2):265–272. https://doi.org/10.1016/j.eururo.2014.02.036
FDA Label for ENTEREG® (alvimopan) Capsules. Published online 2007. Accessed April 2, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
Erpelding SG, Dugan A, Isharwal S, Strup S, James A, Gupta S (2018) Cystectomy for benign disease: readmission, morbidity, and complications. Can J Urol 25(5):9473–9479
Manger JP, Nelson M, Blanchard S, Helo S, Conaway M, Krupski TL (2014) Alvimopan: a cost–effective tool to decrease cystectomy length of stay. Cent European J Urol 67(4):335–341. https://doi.org/10.5173/ceju.2014.04.art4
Cohn JA, Large MC, Richards KA, Steinberg GD, Bales GT (2014) Cystectomy and urinary diversion as management of treatment-refractory benign disease: the impact of preoperative urological conditions on perioperative outcomes. Int J Urol 21(4):382–386. https://doi.org/10.1111/iju.12284
Funding
No sources of funding were utilized for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest or competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hensley, P., Higgins, M., Rasper, A. et al. Efficacy and safety of alvimopan use in benign urinary tract reconstruction. Int Urol Nephrol 53, 77–82 (2021). https://doi.org/10.1007/s11255-020-02621-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-020-02621-9